Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02115


Purpose:

This trial will test the hypothesis that the combination of sirolimus, mycophenolate mofetil, and bortezomib will be effective in preventing both acute and chronic GVHD after reduced intensity allogeneic stem cell transplantation.


Study summary:

The combination of tacrolimus and methotrexate is standard therapy for prevention of GVHD, however, our recent experience has demonstrated that the substitution of sirolimus for methotrexate provides superior GVHD control with reduced transplant-related toxicity. One limitation to the use of calcineurin inhibitors in GVHD prevention is the disruption in Treg function and proliferation. Based on our evolving understanding of the role of Treg in the development of chronic GVHD, we propose a GVHD prophylactic regimen that is effective in prevention of acute GVHD, but by virtue of the maintenance of Treg activity may be able to prevent chronic GVHD. We hypothesize that the substitution of mycophenolate mofetil for tacrolimus as well as the addition of bortezomib may provide similar protection against acute GVHD and prevent chronic GVHD while minimizing renal toxicity after transplantation.


Criteria:

Inclusion Criteria: 1. Patients with hematologic malignancies, who are at high risk of complications after conventional myeloablative transplantation 2. Patients must have a 6/6 matched, related donor. Matching at HLA Class II will be based on PCR of sequence specific primers (SSP). Among family member transplants, serologic matching at Class I is sufficient 3. Patient age greater than 18 4. Performance status 0-2 5. Life expectancy of > 100 days without transplantation 6. Written informed consent must be obtained in all cases from the patient Exclusion Criteria: 1. Pregnancy 2. Prior Allogeneic Stem Cell Transplantation from any donor 3. Evidence of HIV infection or active Hepatitis B or C infection 4. Heart failure uncontrolled by medications 5. Total bilirubin > 2.0 mg/dl that is due to hepatocellular dysfunction 6. AST > 90 7. Cholesterol > 300 mg/dl or Triglycerides > 400 mg/dl while adequately treated 8. Uncontrolled bacterial, viral or fungal infection 9. Requirement for voriconazole at the time of hospital admission


NCT ID:

NCT00548717


Primary Contact:

Principal Investigator
Corey Cutler, MD
Dana-Farber Cancer Institute


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02115
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.